-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inobrodib in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inobrodib in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inobrodib in Refractory Multiple Myeloma Drug Details: Inobrodib (CCS-1477) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inobrodib in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inobrodib in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inobrodib in Relapsed Multiple Myeloma Drug Details: Inobrodib (CCS-1477) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inobrodib in Peripheral T-Cell Lymphomas (PTCL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Inobrodib in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Inobrodib (CCS-1477) is under development for the...
-
Product Insights
Peripheral T-Cell Lymphomas (PTCL) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral T-Cell Lymphomas (PTCL) - Drugs In Development, 2023’, provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NVG-111 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NVG-111 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NVG-111 in Follicular Lymphoma Drug Details: NVG-111 is under development for treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NVG-111 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NVG-111 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NVG-111 in Non-Small Cell Lung Cancer Drug Details: NVG-111...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brepocitinib Tosylate in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brepocitinib Tosylate in Hidradenitis Suppurativa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brepocitinib Tosylate in Hidradenitis Suppurativa Drug Details: Brepocitinib tosylate is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tremelimumab in Metastatic Transitional (Urothelial) Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tremelimumab in Metastatic Transitional (Urothelial) Tract Cancer Drug Details: Tremelimumab (Imjudo) is a human monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Kidney Cancer (Renal Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HTL-0039732 in Kidney Cancer (Renal Cell Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Kidney Cancer (Renal Cell Cancer) Drug Details:...